419 related articles for article (PubMed ID: 26973063)
1. Status of vaccine research and development of vaccines for leishmaniasis.
Gillespie PM; Beaumier CM; Strych U; Hayward T; Hotez PJ; Bottazzi ME
Vaccine; 2016 Jun; 34(26):2992-2995. PubMed ID: 26973063
[TBL] [Abstract][Full Text] [Related]
2. Review on the Drug Intolerance and Vaccine Development for the Leishmaniasis.
Kumari P; Mamud A; Jha AN
Curr Drug Targets; 2023; 24(13):1023-1031. PubMed ID: 37823567
[TBL] [Abstract][Full Text] [Related]
3. Field randomized trial to evaluate the efficacy of the Leish-Tec® vaccine against canine visceral leishmaniasis in an endemic area of Brazil.
Regina-Silva S; Feres AM; França-Silva JC; Dias ES; Michalsky ÉM; de Andrade HM; Coelho EA; Ribeiro GM; Fernandes AP; Machado-Coelho GL
Vaccine; 2016 Apr; 34(19):2233-9. PubMed ID: 26997002
[TBL] [Abstract][Full Text] [Related]
4. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
Osman M; Mistry A; Keding A; Gabe R; Cook E; Forrester S; Wiggins R; Di Marco S; Colloca S; Siani L; Cortese R; Smith DF; Aebischer T; Kaye PM; Lacey CJ
PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
[TBL] [Abstract][Full Text] [Related]
5. Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model.
Gomes R; Teixeira C; Teixeira MJ; Oliveira F; Menezes MJ; Silva C; de Oliveira CI; Miranda JC; Elnaiem DE; Kamhawi S; Valenzuela JG; Brodskyn CI
Proc Natl Acad Sci U S A; 2008 Jun; 105(22):7845-50. PubMed ID: 18509051
[TBL] [Abstract][Full Text] [Related]
6. Vaccine candidates for leishmaniasis: a review.
Nagill R; Kaur S
Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
[TBL] [Abstract][Full Text] [Related]
7. Leishmania vaccine development: exploiting the host-vector-parasite interface.
Reed SG; Coler RN; Mondal D; Kamhawi S; Valenzuela JG
Expert Rev Vaccines; 2016; 15(1):81-90. PubMed ID: 26595093
[TBL] [Abstract][Full Text] [Related]
8.
Lajevardi MS; Gholami E; Taheri T; Sarvnaz H; Habibzadeh S; Seyed N; Mortazavi Y; Rafati S
Front Immunol; 2022; 13():895234. PubMed ID: 35757692
[TBL] [Abstract][Full Text] [Related]
9. Situational analysis of leishmaniases research in Kenya.
Tonui WK
Afr J Health Sci; 2006; 13(1-2):7-21. PubMed ID: 17348738
[TBL] [Abstract][Full Text] [Related]
10. Intradermal Immunization of Leishmania donovani Centrin Knock-Out Parasites in Combination with Salivary Protein LJM19 from Sand Fly Vector Induces a Durable Protective Immune Response in Hamsters.
Fiuza JA; Dey R; Davenport D; Abdeladhim M; Meneses C; Oliveira F; Kamhawi S; Valenzuela JG; Gannavaram S; Nakhasi HL
PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004322. PubMed ID: 26752686
[TBL] [Abstract][Full Text] [Related]
11. Possibilities and challenges for developing a successful vaccine for leishmaniasis.
Srivastava S; Shankar P; Mishra J; Singh S
Parasit Vectors; 2016 May; 9(1):277. PubMed ID: 27175732
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Vaccines Against Leishmania Based on Patent Applications.
Thomaz-Soccol V; Ferreira da Costa ES; Karp SG; Junior Letti LA; Soccol FT; Soccol CR
Recent Pat Biotechnol; 2018; 12(1):21-32. PubMed ID: 28494723
[TBL] [Abstract][Full Text] [Related]
13. Vector transmission of leishmania abrogates vaccine-induced protective immunity.
Peters NC; Kimblin N; Secundino N; Kamhawi S; Lawyer P; Sacks DL
PLoS Pathog; 2009 Jun; 5(6):e1000484. PubMed ID: 19543375
[TBL] [Abstract][Full Text] [Related]
14. Canine Leishmania vaccines: still a long way to go.
Gradoni L
Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
[TBL] [Abstract][Full Text] [Related]
15. Vaccines for visceral leishmaniasis: A review.
Jain K; Jain NK
J Immunol Methods; 2015 Jul; 422():1-12. PubMed ID: 25858230
[TBL] [Abstract][Full Text] [Related]
16. Case study for a vaccine against leishmaniasis.
Alvar J; Croft SL; Kaye P; Khamesipour A; Sundar S; Reed SG
Vaccine; 2013 Apr; 31 Suppl 2():B244-9. PubMed ID: 23598489
[TBL] [Abstract][Full Text] [Related]
17. Antibody responses induced by Leish-Tec®, an A2-based vaccine for visceral leishmaniasis, in a heterogeneous canine population.
Testasicca MC; dos Santos MS; Machado LM; Serufo AV; Doro D; Avelar D; Tibúrcio AM; Abrantes Cde F; Machado-Coelho GL; Grimaldi G; Gazzinelli RT; Fernandes AP
Vet Parasitol; 2014 Aug; 204(3-4):169-76. PubMed ID: 24863572
[TBL] [Abstract][Full Text] [Related]
18. Vaccinomics strategy to concoct a promising subunit vaccine for visceral leishmaniasis targeting sandfly and leishmania antigens.
Ojha R; Pandey RK; Prajapati VK
Int J Biol Macromol; 2020 Aug; 156():548-557. PubMed ID: 32311400
[TBL] [Abstract][Full Text] [Related]
19. Vaccines against leishmaniasis: using controlled human infection models to accelerate development.
Parkash V; Kaye PM; Layton AM; Lacey CJ
Expert Rev Vaccines; 2021 Nov; 20(11):1407-1418. PubMed ID: 34664543
[TBL] [Abstract][Full Text] [Related]
20. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.
Selvapandiyan A; Dey R; Gannavaram S; Solanki S; Salotra P; Nakhasi HL
Vaccine; 2014 Jun; 32(31):3895-901. PubMed ID: 24837513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
